Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse.
Fourteen patients with American Burkitt's lymphoma resistant to conventional chemotherapy were treated with high-dose combination chemotherapy and intensive supportive care. Four patients died shortly after chemotherapy, 3 of an acute carditis. All ten remaining patients demonstrated tumor regression and 3 remain in prolonged complete unmaintained remission 29+, 19+, and 9+ months after treatment. These findings demonstrate that high-dose chemotherapy will benefit some patients with Burkitt's lymphoma unresponsive to conventional chemotherapy, but the medullary and extramedullary toxicity of this treatment strategy remains a formidable obstacle.
D000293:Adolescent; D000328:Adult; D002051:Burkitt Lymphoma / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D009205:Myocarditis / Q000139:chemically induced; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000008:administration & dosage / Q000627:therapeutic use
D003561:Cytarabine; D003520:Cyclophosphamide; D013866:Thioguanine; D002330:Carmustine